Non-Alcoholic Steatohepatitis (NASH) Market to Reflect Impressive Growth by Worldwide Top Key Players Allergan, Cadila Healthcare, Conatus Pharmaceuticals, Genfit
Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition. NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
Download Sample @ https://www.alliedmarketresearch.com/request-sample/224?utm_source=openpr_ss
At present, there is no FDA-approved drug available in the market for the treatment of NASH. Lifestyle interventions are the first-line approach to manage patients with NASH. Based on drug type, the market is segmented into vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. Vitamin E & pioglitazone segment contributes majorly due to effectiveness in a treatment of steatosis, inflammation, hepatocyte ballooning, and scarring in NASH patients.
Based on sales channel, the market is segmented into hospital pharmacy, online provider, and retail pharmacy. At present, the retail pharmacy segment is major revenue generator, and is estimated to show dominance during the forecast period due to the patient convenience and strong presence of retail pharmacies around the world. However, the online provider segment is projected to exhibit the fastest market growth due to rise in awareness of online pharmacies and increase in preference for online purchase of drugs over the traditional methods.
Flat 20% Discount on All License Type...
* Offer Valid Till 20th April 2019
Key Market Players:
• Allergan plc. (Tobira Therapeutics)
• Cadila Healthcare Limited
• Conatus Pharmaceuticals Inc.
• Galmed Pharmaceuticals Ltd
• Gemphire Therapeutics Inc.
• Genfit SA
Key Findings of the Non-alcoholic Steatohepatitis (NASH) Market:
• Based on drug type, the selonsertib & cenicriviroc segment is expected to exhibit the fastest market growth, is projected to grow at a CAGR of 73.7% from 2021 to 2025.
• Based on sales channel, the retail pharmacy segment held more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
• Based on sales channel, the online provider segment exhibited fastest growth and is anticipated to grow at a CAGR of 63.2% from 2021-2025.
• Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 62.62% during the forecast period.
North America accounted approximately one half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. Major factors that driving the market growth in North America are, early diagnosis of the disease, higher prevalence of disease, and strong presence of pipeline drugs. On the other hand, Asia-Pacific is expected to experience the highest CAGR of 62.62% during the forecast period primarily due to growth in prevalence of NASH along with the increase in prevalence of diabetes & obesity and rise in awareness of NASH among the patients. Furthermore, growth in number of R&D activities, development in diagnostic technologies, and increase in healthcare spending is expected to drive the NASH market in Asia-Pacific region.
Browse More Details @ https://www.alliedmarketresearch.com/nonalcoholic-steatohepatitis-NASH-market?utm_source=openpr_ss
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis (NASH) Market to Reflect Impressive Growth by Worldwide Top Key Players Allergan, Cadila Healthcare, Conatus Pharmaceuticals, Genfit here
News-ID: 1692303 • Views: 477
More Releases from Allied Market Research
North America Geogrid Market 2020 Segmentation, Demand, Growth, Trend, Opportuni …
According to the report published by Allied Market Research, the North America geogrid market generated $282.0 million in 2019, and is estimated to reach $408.25 million by 2027, registering a CAGR of 7.0% from 2020 to 2027. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios. Surge in infrastructure development activities across the U.S. and Mexico and superior physical properties
Intravenous Immunoglobulin (IVIG) Market 2020 In-Depth Analysis of Industry Shar …
Global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds
Asthma and COPD Drugs Market Is Expected to Witness a Steady Growth by 2026
"Asthma and COPD Drugs Market by Disease and Medication Class - Global Opportunity Analysis and Industry Forecasts, 2014-2022", projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America
Synthetic Biology Market in Global Industry by Top Companies, Type and Applicati …
Global Synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020). Europe occupies largest share in the global market and would hold-on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014 - 2020. Read Full Report @ https://www.alliedmarketresearch.com/synthetic-biology-market Synthetic biology is at a nascent stage and has recently
More Releases for NASH
NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
Overview of NASH - Opportunity Analysis and Forecasts to 2026
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation
Nonalcoholic Steatohepatitis (NASH) Syndrome - Opportunity Analysis and Forecast …
First described in 1980, Nonalcoholic Steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nonalcoholic Steatohepatitis (NASH) Market Worth US$ 20.0 Billion by 2025
New York, December 12: Market Research Engine has published a new report titled as “Non-Alcoholic Steatohepatitis (NASH) Market by Therapeutics (GFT505, Obeticholic Acid (INT-747), Liraglutide (Victoza) and Simtuzumab, Vitamin E, Pioglitazone, Placebo) - Global Industry Analysis, Trends and Forecast 2016 - 2025” Global Non-Alcoholic Steatohepatitis (NASH) market is expected to cross US$ 20.0 Billion by 2025 growing at a CAGR of more than 10.0% during given forecast period from 2016-2025. Browse Full